CTL Responses to a DNA Vaccine Encod-ing E7 Gene of Human Papillomavirus Type 16 from an Iranian Isolate

Authors

  • Hessam Mirshahabi Department of Virology, School of Medical Sciences, Tarbiat Modares University, Tehran
  • Mahmoud Mahmoudi Immunology Research Center, Mashhad Medical University, Mashhad
  • Maryam Kheirandish Research Center, Iranian Blood Transfusion Organization, Tehran, Iran
  • Mojtaba Meshkat Islamic Azad University, Mashhad Branch, Mashhad
  • Zahra Meshkat Department of Virology, School of Medical Sciences, Tarbiat Modares University, Tehran
  • Zuhair Mohammad Hassan Department of Immunology, School of Medical Sciences, Tarbiat Modares University, Tehran
Abstract:

Background: Cervical cancer is the most prevalent tumor in developing countries and the second most frequent cancer among female population worldwide. Specific human papillomaviruses and, most notably, HPV types 16 and 18 are recognized as being caus-ally associated with cervical carcinomas. The early HPV type 16 genes, E6 and E7, di-rectly participate in the in vitro transformation of primary human keratinocytes and rep-resent an excellent target for immune therapy of HPV related disease. Objective: The aim of this study was the evaluation of the efficacy of a DNA vaccine containing human papillomaviruse type 16 E7 gene (Iranian isolate) in induction of CTL responses in an animal model. Methods: In this study, the expression vector containing HPV type 16 E7 gene was constructed and chosen as a model antigen in the development of a thera-peutic DNA vaccine in an animal model. CTL responses, cytokine assay, lymphocyte stimulation test, CD4 and CD8 staining and flowcytometry were done for evaluating of the immune responses. Results: Our findings indicate that the target DNA vaccine can induce an E7-specific CTL response, which is important in the lysis of infected tumor cells, compared to negative control (p

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

ctl responses to a dna vaccine encod-ing e7 gene of human papillomavirus type 16 from an iranian isolate

background: cervical cancer is the most prevalent tumor in developing countries and the second most frequent cancer among female population worldwide. specific human papillomaviruses and, most notably, hpv types 16 and 18 are recognized as being caus-ally associated with cervical carcinomas. the early hpv type 16 genes, e6 and e7, di-rectly participate in the in vitro transformation of primary ...

full text

CTL responses to a DNA vaccine encoding E7 gene of human papillomavirus type 16 from an Iranian isolate.

BACKGROUND Cervical cancer is the most prevalent tumor in developing countries and the second most frequent cancer among female population worldwide. Specific human papillomaviruses and, most notably, HPV types 16 and 18 are recognized as being causally associated with cervical carcinomas. The early HPV type 16 genes, E6 and E7, directly participate in the in vitro transformation of primary hum...

full text

Developing Michigan Cancer Foundation 7 Cells with Stable Expression of E7 Gene of Human Papillomavirus Type 16

Background: Human papillomavirus (HPV) is responsible for the development of cervical neoplasia.  Infection with human papillomavirus type 16 (HPV-16) is a major risk factor for the development of cervical cancer. The virus encodes three oncoproteins (E5, E6 and E7), of which, the E7 oncoprotein is the major protein involved in cell immortalization and transformation o...

full text

An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.

A new and very promising approach in vaccine development is the application of naked DNA. In comparison to conventional vaccines it offers several advantages, especially if there is a need for the development of low cost vaccines. Infection with high-risk human papillomaviruses (hr-HPVs) is the major risk factor for the development of cervical cancer (cc), the third most common cancer in women ...

full text

Antitumor Response to a Codon-Optimized HPV-16 E7/HSP70 Fusion Antigen DNA Vaccine

Background: Vaccines based on virus-like particles are effective against Human Papilloma Virus (HPV) infection; however, they have not shown a therapeutic effect against HPV-associated diseases. New immunotherapy strategies based on immune responses against tumor antigens can positively affect the clearance of HPV-associated lesions. Objective: To generate two therapeutic fusion DNA vaccines (o...

full text

Strong Immune Responses Induced by a DNA Vaccine Containing HPV16 Truncated E7 C-terminal Linked to HSP70 Gene

Background: Vaccines capable of controlling tumor virus based infections are found difficult to develop due to the consistence latent infection in the host. DNA vaccines are attractive tools for the development of HPV vaccines and inducing antigen-specific immunity owing to the stability, simplicity of delivery, safety and cost effectiveness. However, there is a need to increase their potency b...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 5  issue 2

pages  82- 91

publication date 2008-06-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023